A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 495,547 shares of ASND stock, worth $67.6 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
495,547
Holding current value
$67.6 Million
% of portfolio
0.2%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$113.0 - $153.43 $56 Million - $76 Million
495,547 New
495,547 $74 Million
Q1 2023

May 15, 2023

BUY
$104.9 - $126.78 $41.6 Million - $50.3 Million
396,400 Added 105.79%
771,110 $82.7 Million
Q4 2022

Feb 14, 2023

SELL
$99.42 - $131.97 $943,495 - $1.25 Million
-9,490 Reduced 2.47%
374,710 $45.8 Million
Q3 2022

Nov 14, 2022

BUY
$84.03 - $110.23 $32.3 Million - $42.4 Million
384,200 New
384,200 $39.7 Million
Q1 2022

May 16, 2022

SELL
$102.18 - $135.75 $11.5 Million - $15.2 Million
-112,200 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$127.1 - $169.66 $2.53 Million - $3.37 Million
19,891 Added 21.55%
112,200 $15.1 Million
Q3 2021

Nov 15, 2021

BUY
$112.67 - $176.92 $812,238 - $1.28 Million
7,209 Added 8.47%
92,309 $14.7 Million
Q2 2021

Aug 16, 2021

BUY
$121.62 - $145.29 $6.09 Million - $7.28 Million
50,100 Added 143.14%
85,100 $11.2 Million
Q1 2021

May 17, 2021

SELL
$124.92 - $173.33 $836,964 - $1.16 Million
-6,700 Reduced 16.07%
35,000 $4.51 Million
Q4 2020

Feb 16, 2021

BUY
$151.2 - $182.76 $6.31 Million - $7.62 Million
41,700 New
41,700 $6.96 Million
Q2 2020

Aug 14, 2020

SELL
$110.87 - $156.01 $8.05 Million - $11.3 Million
-72,600 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$97.01 - $145.11 $7.04 Million - $10.5 Million
72,600 New
72,600 $8.18 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.